600 patients66,869 observations120 daysLIVE
← Patients

Patient P-01887

Synthetic patientNBL-101 · Day 118 · 55–64 · F · baseline S12Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
86%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 started — Baseline state S12
  2. Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  3. Day 72 ME-01 recommended — Monitoring Escalation ME-01
  4. Day 73 Patient accepted — Started ME-01 in the companion
  5. Day 76 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days
  • Nutritional resilience-8
  • GI instability-2

What helped?

  • Monitoring Escalation ME-01Day 72
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
90%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
66.1/100
worsening · +8.5 vs previous 14 d
Toxicity
Blood
51.1/100
worsening · +2.9 vs previous 14 d
Sleep quality
Wearable
39.1/100
worsening · -8.5 vs previous 14 d
Energy level
Daily log
2.5/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log
6.1/10
worsening · +0.7 vs previous 14 d
Steps
Wearable
6,936
worsening · -451 vs previous 14 d
Adherence
Companion
44.8 %
stable · +0.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading drifting · 21 from the failing basin, 71 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 124 similar · onset 8 d · confidence 94%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 76%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 76%
Would not help
  • Keep fat low
    GI +7.4 next day on high-intake days · n 23
  • Keep simple carbs low
    GI +6.3 next day on high-intake days · n 21
  • Keep histamine low
    GI +6.2 next day on high-intake days · n 17
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +7.4detractor · 95%
  • Simple carbohydrates
    +6.3detractor · 95%
  • Histamine load
    +6.2detractor · 95%
  • Insoluble fibre
    +5.4detractor · 95%
  • Spicy / capsaicin
    +4.3detractor · 73%
  • Alcohol
    -1.8no signal · 29%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity ↓80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 66 and rising
  • Drug metabolism and exposure ↑60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 51
  • Butyrate / short-chain fatty acid production ↓55
    • MicrobiomeButyrate capacity 42/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling ↑50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 61
  • Autonomic recovery ↓45
    • WearableResting HR 78 bpm
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 2.8 · butyrate capacity 42/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
47 ms
Sleep
6.1 h
Steps
6,343
Resting HR
79 bpm
Daily log: GI score 66, nutritional resilience 29, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0181342%S01NP-02no change40
P-0132736%S01GI-04improved56
P-0168829%S01GI-04improved40
P-0131027%S01——57
P-0187723%S01CR-01improved67
P-0182119%S01——58
P-0163533%S02GI-04improved49
P-0145231%S02GI-04improved46
P-0145926%S02——51
P-0149819%S02——56
P-0149918%S02——65
P-0173641%S03ME-01improved46